We thank the family members and friends of the patients who provided extraordinary care at home to their patients; staff members of the laboratories and radiology centers who provided their services; pharmacies who provided timely medications and equipment; and providers of the oxygen cylinders. The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.
Clark JD, Flanagan ME, Telliez J, 2014. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57: 5023–5038.
McInnes IB et al., 2019. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 21: 183.
Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Heide RSV, 2020. Pulmonary and cardiac pathology in COVID-19: the first autopsy series from New Orleans. Lancet Respir Med 8: 681–686.
Perez N, Virelizier J-L, Arenzana-Seisdedos F, Fischer A, Griscelli C, 1984. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr 104: 569–573.
Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkem R, Dulli A, Hayek R, Parvez K, Singh S, 2021. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes 5: 605–613.
- Search Google Scholar
- Export Citation
Hayek ME Mansour M Ndetan H Burkes Q Corkem R Dulli A Hayek R Parvez K Singh S 2021. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes 5: 605– 613.
Ramakrishnan S et al., 2021. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 9: 763–772.
Lauder SN et al., 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol 43: 2613–2625.
Wollenhaupt J et al., 2019. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21: 89.